Abstract |
Actinic keratosis, a frequent carcinoma in situ of non- melanoma skin cancer (NMSC), can transform into life-threatening cutaneous squamous cell carcinoma. Current treatment is limited due to low complete clearance rates and asks for novel therapeutic concepts; the novel purine nucleotide analogue OxBu may be an option. In order to enhance skin penetration, solid lipid nanoparticles (SLN, 136-156 nm) were produced with an OxBu entrapment efficiency of 96.5 ± 0.1%. For improved preclinical evaluation, we combined tissue engineering with clinically used keratin-18 quantification. Three doses of 10(-3) mol/l OxBu, dissolved in phosphate-buffered saline as well as loaded to SLN, were effective on reconstructed NMSC. Tumour response and apoptosis induction were evaluated by an increase in caspase-cleaved fragment of keratin-18, caspase-7 activation as well as by reduced expression of matrix metallopeptidase-2 and Ki-67. OxBu efficacy was superior to equimolar 5-fluorouracil solution, and thus the drug should be subjected to the next step in preclinical evaluation.
|
Authors | C Ali-von Laue, C Zoschke, N Do, D Lehnen, S Küchler, W Mehnert, T Blaschke, K D Kramer, J Plendl, G Weindl, H C Korting, D Hoeller Obrigkeit, H-F Merk, M Schäfer-Korting |
Journal | Skin pharmacology and physiology
(Skin Pharmacol Physiol)
Vol. 27
Issue 4
Pg. 173
( 2014)
ISSN: 1660-5535 [Electronic] Switzerland |
PMID | 24503861
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Organophosphonates
- Guanosine
|
Topics |
- Administration, Topical
- Animals
- Drug Delivery Systems
- Guanosine
(analogs & derivatives)
- Humans
- Nanoparticles
(administration & dosage)
- Organophosphonates
(administration & dosage)
- Skin Neoplasms
(drug therapy)
- Tissue Engineering
|